NBIX241220P80000
- 1.94
- 0.000.00%
Neurocrine Biosciences Newsroom
J.P. Morgan Maintains Neurocrine Biosciences(NBIX.US) With Buy Rating
Neurocrine Wins FDA Nod for CAH Therapy
Express News | Neurocrine Biosciences Inc - Crenessity Expected to Be Available in One Week
Express News | FDA: Crenessity Approved as Adjunctive Treatment for Adults & Pediatric Patients 4 Years of Age & Older With Classic Congenital Adrenal Hyperplasia
Express News | FDA Approves Neurocrine Biosciences' Crenessity- Website
FDA Approves New Treatment for Congenital Adrenal Hyperplasia
"Laggard" Stocks With Expanding FCF Margins and Attractive FCF Yields – Goldman
Investors in Neurocrine Biosciences (NASDAQ:NBIX) Have Seen Notable Returns of 53% Over the Past Three Years
Neurocrine Biosciences To Present At Evercore HealthCONx Conference; Webcast At 10:50 AM ET
Screening For Black Friday Bargains In The Stock Market
Why Neurocrine Biosciences (NBIX) Is the Most Profitable Pharmaceutical Stock Right Now?
Neurocrine (NBIX) Receives a Hold From RBC Capital
Short Stock Ideas From Each Sector With Earnings Quality in the Bottom 20%
Neurocrine Biosciences to Participate at Investor Conferences in December
Trending Stocks Today | ZenaTech up 7.47% Post-Market
Congenital Adrenal Hyperplasia Landscape Research 2024: Comprehensive Insights About 8+ Pipeline Drugs Featuring Neurocrine Biosciences, Spruce Biosciences, Lundbeck, and HBM Alpha Therapeutics
Stifel Maintains Neurocrine Biosciences(NBIX.US) With Buy Rating, Maintains Target Price $166
Neurocrine Biosciences To Present At Jefferies London Healthcare Conference; Webcast At 8:30 AM ET
Neurocrine Biosciences To Present At Stifel Healthcare Conference; Webcast At 10:55 AM ET
US Manufacturing Index Rises To 43, Highest Since 2020